Lumos Pharma

98 articles about Lumos Pharma

• Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

  3/20/2024

  Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that on Thursday, March 14, 2024, the Company received a Notice of Allowance from the US Patent and Trade Office (USPTO) for claims in its patent application number PCT/US22/050700 titled “Compactable Oral Formulations of Ibutamoren.”

• Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

  3/7/2024

  Lumos Pharma, Inc. (NASDAQ:LUMO) today announced financial results for the year ended December 31, 2023 and provided an update on clinical and regulatory activity.

• Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

  2/26/2024

  Lumos Pharma, Inc. announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024.

• Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference

  2/5/2024

  Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.

• Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

  1/4/2024

  Lumos Pharma, Inc., a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer, effective January 1, 2024.

• Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

  11/21/2023

  Lumos Pharma, Inc., a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency, announced that the Company will host a key opinion leader webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail.

• Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November

  11/20/2023

  Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference being held November 28th – 30th in New York City.

• Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

  11/7/2023

  Lumos Pharma, Inc. (NASDAQ:LUMO) today announced that topline results met primary and secondary endpoints for its Phase 2 Dose-Finding OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic (PK/PD) OraGrowtH212 Trial evaluating oral LUM-201 for subjects with moderate pediatric growth hormone deficiency (PGHD) who screened PEM-positive utilizing Lumos Pharma’s predictive enrichment marker (PEM) strategy.

• Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

  11/7/2023

  Lumos Pharma, Inc. announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic trial met all primary and secondary endpoints.

• Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting

  9/26/2023

  Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that an analysis of interim data from its OraGrowtH212 Trial was given as an oral presentation at the 2023 annual meeting of the European Society for Paediatric Endocrinology (ESPE),

• Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

  9/14/2023

  Lumos Pharma, Inc. announced today that an abstract reviewing interim data from its OraGrowtH212 Trial has been accepted for oral presentation at the 2023 annual meeting of the European Society for Paediatric Endocrinology, to be held in The Hague, Netherlands.

• Lumos Pharma Announces Participation in Investor Conferences in September

  9/7/2023

  Lumos Pharma, Inc. announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th – 13th.

• Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape

  8/22/2023

  Lumos Pharma, Inc. announced that an independent, key opinion leader panel of five pediatric endocrinologists will participate in a webinar for discussion of PGHD, the current injectable therapeutic landscape, and the potential for an oral treatment option for this indication.

• Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update

  8/9/2023

  Lumos Pharma, Inc., a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency through Phase 2 clinical trials, announced financial results for the second quarter ended June 30, 2023.

• Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023

  7/26/2023

  Lumos Pharma, Inc. announced it will report its second quarter 2023 financial results after market close on Wednesday, August 9, 2023.

• Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit

  7/12/2023

  Lumos Pharma, Inc. will participate in the Oppenheimer 2023 Life Sciences Summit to be held July 18th – 20th in Montauk, NY, during which discussions with investors will take place.

• Lumos Pharma Announces Departure of Chief Medical Officer

  6/28/2023

  Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that Chief Medical Officer (CMO) Dr. David B. Karpf is departing the company to pursue other opportunities, effective June 29th.

• Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

  6/21/2023

  Lumos Pharma, Inc. (NASDAQ:LUMO) is hosting today a virtual Key Opinion Leader (KOL) Webinar where Drs. Fernando Cassorla and Michael Tansey will highlight the encouraging new data and analysis on oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the Endocrine Society (ENDO) Annual Meeting.

• Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference

  5/31/2023

  Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 2023 BIO International Convention held June 5-8, 2023 in Boston and the Jefferies Healthcare Conference held June 7-9, 2023 in New York City.

• Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st

  5/25/2023

  Lumos Pharma, Inc. announced that interim data from its OraGrowtH210 and OraGrowtH212 Trials will be reviewed in two oral presentations in Session OR21 – “Update on Growth Disorders” at the 2023 Annual Meeting of the Endocrine Society, held in Chicago, Illinois, June 15-18, 2023.